The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Real-world trends of CRS and ICANS among patients receiving axi-cel for R/R LBCL: a CIBMTR Report
Frederick Locke, MD, Moffitt Cancer Center, Tampa, FL, presents the findings of a Center for International Blood and Marrow Transplant Research (CIBMTR) report, which looked at real-world trends of cytokine release syndrome (CRS) and neurologic toxicities among patients treated with axicabtagene ciloleucel (axi-cel) for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Dr Locke notes that the incidence and duration of CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) decreased between 2017 and 2023, suggesting improvements in management practices. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Really excited to be here at the 66th ASH annual meeting talking about some of the work we’re doing. CIBMTR collected data on patients who received axicabtagene ciloleucel for treatment of their large B-cell lymphoma. In over 1,000 treated patients from over 100 centers, we took a look at their toxicity outcomes based upon the time those patients were treated, split them up into three intervals from 2017 to 2019, 2020 to 2021, and 2022 to 2023...
Really excited to be here at the 66th ASH annual meeting talking about some of the work we’re doing. CIBMTR collected data on patients who received axicabtagene ciloleucel for treatment of their large B-cell lymphoma. In over 1,000 treated patients from over 100 centers, we took a look at their toxicity outcomes based upon the time those patients were treated, split them up into three intervals from 2017 to 2019, 2020 to 2021, and 2022 to 2023. And when looking at the incidence of CRS in those patients, the earlier treated patients in the 2017 era had an over 80% chance of developing cytokine release syndrome. And that dropped to about 75% for patients treated in 2022 and 2023. So there’s evolution in the onset of the CRS and we think that’s really due to the management of practices.
Also the duration of CRS was shorter in patients who were treated later on, maybe due to factors such as disease and the disease burden as well as the way we’re treating these patients. And that held up even in multivariate analysis.
When we looked at neurologic toxicities or ICANS, similarly the rates of ICANS went down in patients who were treated later on in that later time period. And the rates of severe CRS and severe ICANS similarly went down. And so we’re learning better as a community how to manage these treatments. So glad to be here at ASH and have this data presented.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Aptitude Health: Honoraria; American Society of Hematology: Honoraria, Other: travel, accomodation, expenses; BioPharma Communications CARE Education: Honoraria; A2: Consultancy; Allogene: Consultancy, Research Funding; Amgen: Consultancy; Bluebird Bio: Consultancy; Bristol-Myers Squibb: Consultancy, Research Funding; Calibr: Consultancy; Caribou: Consultancy; Kite, a Gilead Company: Consultancy, Other: institutional, travel, accomodation, expenses, Research Funding; Allogene: Other: Institutional, Research Funding; CERo Therapeutics: Research Funding; Moffitt Cancer Center: Patents & Royalties; Communications CARE Education: Honoraria; Clinical Care Options Oncology: Honoraria; Imedex: Honoraria; Society for Immunotherapy of Cancer: Honoraria; Cowen: Consultancy; EcoR1: Consultancy; Gerson Lehrman Group (GLG): Consultancy; Iovance: Consultancy; Janssen: Consultancy; Legend Biotech: Consultancy; Novartis: Consultancy, Research Funding; Sana: Consultancy; Umoja: Consultancy; Pfizer: Consultancy; 2SeventyBio: Other: Institutional, Research Funding; National Cancer Institute: Other: Institutional, Research Funding; Leukemia and Lymphoma Society Scholar in Clinical Research: Other: Institutional, Research Funding.
